Skip to content
value.today

Eiger Biopharmaceuticals Inc.

🇺🇸 Palo Alto, California, USABiotechnologyFounded 2008
Total raised
$29 M
3 rounds on record
Latest round
$6 M
Nov 2015
First round on record
Dec 2008
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Eiger Biopharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2015$6 MNo. 3$2 to $10 million

Eiger Biopharmaceuticals Inc.: Raise no. 3, Nov 2015

Investors in this round

4 investors had bought by the notice of Nov 20, 2015: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Cory · Executive Officer, Director
  • Ed Engleman · Director
  • Jeffrey Glenn · Director
  • Nina Kjellson · Director
  • Thomas Dietz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Cory, President and CEO. Newest notice filed Nov 20, 2015. Read the notice at the SEC.

debt, optionsSEC
Apr 2011$14 MNo. 2$10 to $50 million

Eiger Biopharmaceuticals Inc.: Raise no. 2, Apr 2011

Investors in this round

8 investors had bought by the notice of Mar 24, 2015: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $15 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Sale and issuance of Series A-1 Preferred Stock and the underlying Common Stock issuable upon conversion thereof.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Cory · Executive Officer, Director
  • Ed Engleman · Director
  • Jeffrey Glenn · Director
  • Nina Kjellson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Cory, President and CEO. Newest notice filed Mar 24, 2015 (7 amendments). Read the notice at the SEC.

equitySEC
Dec 2008$8 MNo. 1$2 to $10 million

Eiger Biopharmaceuticals Inc.: Raise no. 1, Dec 2008

Investors in this round

9 investors had bought by the notice of Sep 20, 2010: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Sale and issuance of Series A Preferred Stock and the underlying Common Stock issuable upon conversion thereof.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Cory · Executive Officer, Director
  • Glen Sato · Executive Officer
  • Keith Vendola · Executive Officer
  • Wenjin Yang · Executive Officer
  • Ed Engleman · Director
  • Jeffrey Glenn · Director
  • Nina Kjellson · Director
  • Paul Truex · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Cory, President and CEO. Newest notice filed Sep 20, 2010. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Eiger Biopharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2015).

    SEC Form D · Nov 2015

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Nov 2015

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Eiger Biopharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Eiger Biopharmaceuticals Inc.
NameRoleNamed in
David CoryExecutive officerNov 2015
Glen SatoExecutive officerAug 2012
Keith VendolaExecutive officerSep 2010
Wenjin YangExecutive officerSep 2010
David CoryDirectorNov 2015
Ed EnglemanDirectorNov 2015
Jeffrey GlennDirectorNov 2015
Nina KjellsonDirectorNov 2015
Thomas DietzDirectorNov 2015
Paul TruexDirectorAug 2012